Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;162(6):774-82.
doi: 10.1111/bjh.12458. Epub 2013 Jul 11.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

Sameer A Parikh  1 , Kari G Rabe, Timothy G Call, Clive S Zent, Thomas M Habermann, Wei Ding, Jose F Leis, Susan M Schwager, Curtis A Hanson, William R Macon, Neil E Kay, Susan L Slager, Tait D Shanafelt
Affiliations

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

Sameer A Parikh et al. Br J Haematol. 2013 Sep.

Abstract

Nearly all information about patients with chronic lymphocytic leukaemia (CLL) who develop diffuse large B-cell lymphoma [Richter syndrome (RS)] is derived from retrospective case series or patients treated on clinical trials. We used the Mayo Clinic CLL Database to identify patients with newly diagnosed CLL between January 2000 and July 2011. Individuals who developed biopsy-proven RS during follow-up were identified. After a median follow-up of 4 years, 37/1641 (2·3%) CLL patients developed RS. The rate of RS was approximately 0·5%/year. Risk of RS was associated with advanced Rai stage at diagnosis (P < 0·001), high-risk genetic abnormalitites on fluorescence in situ hybridization (P < 0·0001), unmutated IGHV (P = 0·003), and expression of ZAP70 (P = 0·02) and CD38 (P = 0·001). The rate of RS doubled in patients after treatment for CLL (1%/year). Stereotyped B-cell receptors (odds-ratio = 4·2; P = 0·01) but not IGHV4-39 family usage was associated with increased risk of RS. Treatment with combination of purine analogues and alkylating agents increased the risk of RS three-fold (odds-ratio = 3·26, P = 0·0003). Median survival after RS diagnosis was 2·1 years. The RS prognosis score stratified patients into three risk groups with median survivals of 0·5 years, 2·1 years and not reached. Both underlying characteristics of the CLL clone and subsequent CLL therapy influence the risk of RS. Survival after RS remains poor and new therapies are needed.

Keywords: Richter syndrome survival score; aggressive lymphoma; purine analogues; stem cell transplantation; transformation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Rate of Richter syndrome in the entire cohort (black solid line). Rate of Richter syndrome in those who received CLL treatment (red dashed line, initiation of CLL treatment considered time zero)
Figure 2
Figure 2
A: Overall Survival of all patients with Richter Syndrome B: Overall Survival of RS patients who received prior therapy for CLL compared to those who did not
Figure 2
Figure 2
A: Overall Survival of all patients with Richter Syndrome B: Overall Survival of RS patients who received prior therapy for CLL compared to those who did not
Figure 3
Figure 3
Overall Survival of all Richter syndrome patients according to the RS score *: RS score as described by Tsimberidou et al. Each of the following characteristics at the time of diagnosis of RS gets one point: ECOG performance status of 2–4, LDH >1.5× normal, PLT <100, Tumour size >5 cm and >1 prior therapy for CLL. Patients are then assigned to one of three risk groups based on their calculated RS score: 0 or 1, low risk; 2 or 3, intermediate risk; 4 or 5, high risk.
See this image and copyright information in PMC

References

    1. Armitage JO, Dick FR, Corder MP. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer. 1978;41:422–427. - PubMed
    1. Aydin S, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 2008;111:5646–5653. - PubMed
    1. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239. - PubMed
    1. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997. - PubMed
    1. Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P. Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology. 2012;30:2211–2217. - PubMed

Publication types

MeSH terms